Premium
Non‐peptidic small molecule inhibitors against Bcl‐2 for cancer therapy
Author(s) -
Azmi Asfar S.,
Mohammad Ramzi M.
Publication year - 2009
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.21567
Subject(s) - apoptosis , regulator , mode of action , small molecule , cancer therapy , cancer cell , cancer research , cancer , programmed cell death , chemistry , biology , microbiology and biotechnology , biochemistry , gene , genetics
A critical regulator of the apoptotic machinery is the Bcl‐2 family proteins whose over expression confers a protective effect on malignant cells against death signals of apoptosis. Cancer cells that are resistant to various anti‐cancer drugs and treatment regimen are found to over express these Bcl‐2 proteins such as Bcl‐2, Bcl‐X L , Mcl‐1, Bcl‐w, and A1/Bfl1. In recent years there has been an exponential growth in the identification as well as synthesis of non‐peptidic cell permeable small‐molecule inhibitors (SMIs) of protein–protein interaction. The focus of this article is on inhibitors of anti‐apoptotic protein Bcl‐2. This review summarizes an up to date knowledge of the available SMIs, their mode of action as well as their current status in preclinical as well as clinical development. J. Cell. Physiol. 218: 13–21, 2009. © 2008 Wiley‐Liss, Inc.